Beta Bionics to Announce Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026
BBNXIRVINE, Calif., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its fourth quarter and full year 2025 financial results after the financial markets close on Tuesday, February 17, 2026. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company’s fourth quarter and full year 2025 performance.
Beta Bionics, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights - BBNX
BBNXLOS ANGELES, Jan. 15, 2026 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Beta Bionics, Inc. ("Beta Bionics" or "the Company") (NASDAQ: BBNX) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on...
BBNX Investors Have Opportunity to Join Beta Bionics, Inc. Fraud Investigation with the Schall Law Firm
BBNXLOS ANGELES, Jan. 15, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Beta Bionics, Inc. ("Beta Bionics" or "the Company") (NASDAQ: BBNX) for violations of the securities laws. The...
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
BBNXNEW YORK--(BUSINESS WIRE)---- $BBNX #BBNX--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX). Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. The investigation focuses on whether the Company
Securities Fraud Investigation Into Beta Bionics, Inc. (BBNX) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
BBNXLOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) on behalf of investors concerning the Company’s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON BETA BIONICS, INC. (BBNX), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On January 8, 2026, Beta Bionics released preliminary fourth q
Beta Bionics to Pre-Announce Topline Fourth Quarter 2025 Financial Results the Week of January 5, 2026
BBNXIRVINE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX) (the “Company”), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to pre-release its topline fourth quarter 2025 financial results the week of January 5, 2026.
Beta Bionics Announces Participation at Upcoming Investor Conferences
BBNXIRVINE, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at three upcoming investor conferences (all Eastern Time):
Lake Street Assumes Beta Bionics at Buy, Announces Price Target of $30
BBNXGoldman Sachs Initiates Coverage On Beta Bionics with Neutral Rating, Announces Price Target of $16
BBNXWolfe Research Initiates Coverage On Beta Bionics with Outperform Rating, Announces Price Target of $20
BBNXBeta Bionics Raises FY2025 Sales Guidance from $80.00M-$85.00M to $82.00M-$87.00M vs $82.68M Est
BBNXBeta Bionics Q1 EPS $(0.93) Misses $(0.46) Estimate, Sales $17.64M Beat $16.15M Estimate
BBNXBeta Bionics Sees 2025 Revenue $80M-$85M vs $85.097M
BBNXBeta Bionics Q4 2024 GAAP EPS $(2.72) Beats $(2.91) Estimate, Sales $20.400M Beat $20.187M Estimate
BBNXThis Smithfield Foods Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
BBNXStifel Initiates Coverage On Beta Bionics with Buy Rating, Announces Price Target of $25
BBNXLake Street Initiates Coverage On Beta Bionics with Buy Rating, Announces Price Target of $30
BBNXPiper Sandler Initiates Coverage On Beta Bionics with Overweight Rating, Announces Price Target of $26
BBNXLeerink Partners Initiates Coverage On Beta Bionics with Outperform Rating, Announces Price Target of $28
BBNXThis Palantir Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
BBNXLadenburg Thalmann Initiates Coverage On Beta Bionics with Buy Rating, Announces Price Target of $31
BBNXBaird Initiates Coverage On Beta Bionics with Neutral Rating, Announces Price Target of $20
BBNX